Detalhe da pesquisa
1.
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma.
Eur J Nucl Med Mol Imaging
; 48(6): 1902-1914, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33196921
2.
Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable.
Acta Oncol
; 60(11): 1481-1488, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34425735
3.
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003.
Eur J Nucl Med Mol Imaging
; 46(11): 2311-2321, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31309259
4.
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
Eur J Nucl Med Mol Imaging
; 45(7): 1233-1241, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29470615
5.
Combination of 177 Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin's lymphoma.
Eur J Haematol
; 101(4): 522-531, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29993152
6.
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?
Mol Imaging Biol
; 24(5): 807-817, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35486292
7.
89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma.
Sci Rep
; 12(1): 6286, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35428777
8.
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.
PLoS One
; 17(4): e0267543, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35486574
9.
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.
Eur J Nucl Med Mol Imaging
; 37(1): 93-102, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19593562
10.
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003.
PLoS One
; 15(3): e0230526, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32187209
11.
177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma.
J Nucl Med
; 61(10): 1468-1475, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32245896
12.
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Blood Adv
; 4(17): 4091-4101, 2020 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877524
13.
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest.
Leukemia
; 34(5): 1315-1328, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31836849
14.
The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines.
Front Oncol
; 9: 1301, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31850205
15.
Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
Int J Radiat Oncol Biol Phys
; 72(1): 186-92, 2008 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18722269
16.
Overexpression of human OGG1 in mammalian cells decreases ultraviolet A induced mutagenesis.
Cancer Lett
; 267(1): 18-25, 2008 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-18406515
17.
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
J Nucl Med
; 59(4): 704-710, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28848035
18.
Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th.
Cancer Biother Radiopharm
; 22(4): 469-79, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17803441
19.
Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability.
Cancer Biother Radiopharm
; 22(3): 431-7, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17651051
20.
A one-step method for determining the maximum number of bound antibodies, and the affinity and association rate constants for antibody binding.
Nucl Med Commun
; 28(9): 742-7, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17667754